Cefuroxime

C difficile risk
Medium
Oral Bioavailability
Moderate
Cost
PO Non-formulary for inpatients

Dosing

PO

  • PNA/SSTI: 500 mg PO q12h

  • UTI, mild SSTI: 250 mg PO q12h

IV

  • 1.5 gm IV q8h

CrCl <10CrCl 10 - 29CrCl > 30PO

  • PNA/SSTI: 500 mg q48h

  • UTI, mild SSTI: 250 mg PO q48h

IV

  • 1.5 gm IV q24hPO

  • PNA/SSTI: 500 mg q24h

  • UTI, mild SSTI: 250 mg PO q24h

IV

  • 1.5 gm IV q12hUsual dosing

PO

  • 250-500 mg q48 + a supplemental dose after each HD session

IV

  • 1.5 gm q24 + a supplemental dose after each HD session

General Information

  •  Community acquired pneumonia with a macrolide

  •  Intraabdominal infection

  •  Epiglottitis

  •  Allergy (immediate & delayed)

  •  Positive Coombs

  •  Cytopenias

  •  GI upset

  •  Diarrhea

  •  Abnormal liver enzymes

No significant interactions.

Antimicrobial class: 2nd Generation Cephalosporin

Pregnancy category: B

Average serum half life: 2 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.